Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APGE Apogee Therapeutics

Closed Good Friday 04-17 16:00:00 EDT

33.11

+1.07

+3.34%

盘后33.00

-0.11-0.33%

17:11 EDT

High33.38	Low31.60	Vol347.97K
Open32.08	D1 Closing32.04	Amplitude5.56%
Mkt Cap1.92B	Tradable Cap1.29B	Total Shares58.09M
T/O11.34M	T/O Rate0.89%	Tradable Shares39.04M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":33.11,"timestamp":1744920000000,"preClose":32.04,"halted":0,"volume":347971,"hourTrading":{"tag":"盘后","latestPrice":33,"preClose":33.11,"latestTime":"17:11 EDT","volume":5622,"amount":186124.08,"timestamp":1744924304458},"delay":0,"floatShares":39041575,"shares":58087357,"eps":-3.300106,"marketStatus":"Closed Good Friday","change":1.07,"latestTime":"04-17 16:00:00 EDT","open":32.08,"high":33.38,"low":31.6,"amount":11336437.946106,"amplitude":0.055556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.300106,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":32.04,"preHourTrading":{"tag":"盘前","latestPrice":32.13,"preClose":32.04,"latestTime":"09:29 EDT","volume":19,"amount":611.83002,"timestamp":1744896598411},"postHourTrading":{"tag":"盘后","latestPrice":33,"preClose":33.11,"latestTime":"17:11 EDT","volume":5622,"amount":186124.08,"timestamp":1744924304458},"volumeRatio":0.49655341992782914,"impliedVol":0.9364,"impliedVolPercentile":0.9243},"requestUrl":"/m/hq/s/APGE","defaultTab":"news","newsList":[{"id":"2525189456","title":"Apogee Therapeutics price target lowered to $78 from $80 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2525189456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525189456?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:35","pubTimestamp":1744115733,"startTime":"0","endTime":"0","summary":"BofA analyst Tim Anderson lowered the firm’s price target on Apogee Therapeutics (APGE) to $78 from $80 and keeps a Buy rating on the shares after ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-lowered-to-78-from-80-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-lowered-to-78-from-80-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2524557116","title":"Apogee Therapeutics Inc : Jefferies Raises Target Price to $88 From $86","url":"https://stock-news.laohu8.com/highlight/detail?id=2524557116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524557116?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:45","pubTimestamp":1743511547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF0V0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2519856750","title":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856750?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:47","pubTimestamp":1741880850,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCB","LU0162691827.USD","LU0238689110.USD","KYMR","TRIB","BK4570","LU0096364046.USD","LU2250418816.HKD","PCAR","LU2506952170.USD","LU2317271919.USD","LU0276348264.USD","MNTK","AEO","LYV","LU1043141123.HKD","ETNB","ATEN","AEYE","LU2430703178.SGD","IE00BMPRXQ63.HKD","BBW","APGE","NN","ALKT","LU1496350171.SGD","NEM","DLTR","GIII","NVAX","NOVA","SPIR","KNSA","FOSL","TARS","LU2498475776.HKD","IE00BJJMRX11.SGD","LU2065169927.USD","MGTX","AVAH"],"gpt_icon":1},{"id":"2519683069","title":"BUZZ-Citi initiates Apogee with \"buy\" rating on potential for eczema drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2519683069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519683069?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 22:17","pubTimestamp":1741875471,"startTime":"0","endTime":"0","summary":"BUZZ-Citi initiates Apogee with \"buy\" rating on potential for eczema drug** Brokerage Citi starts coverage on Apogee Therapeutics APGE.O with \"buy\" rating** Brokerage sets PT at $95, representing more than double upside to the stock's last close** Brokerage sees peak combined adjusted revenues of $2.2 billion from co's experimental drug candidate APG777 to treat atopic dermatitis  or often called as eczema, a type of skin disease, and asthma     ** Citi says \"capturing a fraction of the Dupixent patient in AD is itself a multi-billion dollar opportunity\"** Dupixent is jointly developed by Sanofi SASY.PA and Regeneron REGN.O for patients with AD and asthma** Brokerage believes physicians are unlikely to switch well-managed patients from Dupixent to APG777 unless the latter shows comparable or superior efficacy with similar safety profile ** All eight brokerages covering the stock rate it at \"buy\" or higher, their median PT is $93.5** APGE has fallen 44.4% in the past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW11O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","REGN"],"gpt_icon":0},{"id":"2519288030","title":"Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519288030","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519288030?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:13","pubTimestamp":1741864400,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has an average rating of buy and mean price target of $93.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2519878538","title":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2519878538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519878538?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:56","pubTimestamp":1741863404,"startTime":"0","endTime":"0","summary":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty   ** Brokerage Citi initiates coverage on eight small and mid-cap  biotechs - 89bio ETNB.O, Apogee Therapeutics APGE.O, Avidity Biosciences RNA.O, BioNTech 22UAy.DE, Kiniksa Pharmaceuticals KNSA.O, Kymera Therapeutics KYMR.O, Moderna MRNA.O and PTC Therapeutics PTCT.O** Citi suggests SMid biotechs could be a good alternative to larger-cap stocks amid healthcare policy uncertainty** Recent economic uncertainties, including increased tariffs and slowing economic growth, have \"underscored the defensive attributes\" of biotech and pharma stocks, brokerage says ** Higher-growth large caps such as Eli Lilly LLY.N and Vertex Pharma VRTX.O are likely able to absorb potential policy headwinds and \"catalyst-driven\" SMid biotechs are \"insulated from macro uncertainties\" - Citi** YTD, S&P500 Health Care index .SPXHC has grown ~5%, NYSE Arca Pharmaceutical Index .DRG has gained ~6% and NASDAQ Biotechnology Inde","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","BK4139","VRTX","LU0238689110.USD","IE00BFTCPJ56.SGD","LU2211815571.USD","PTCT","RNA","APGE","LU1291159041.SGD","LU0006306889.USD","ETNB","IE00B894F039.SGD","LU1280957306.USD","LU1720051017.SGD","SG9999014898.SGD","MRNA","SG9999018865.SGD","SGXZ81514606.USD","LU1868837136.USD","LU1868836591.USD","IE0002141913.USD","LU0097036916.USD","LU1551013342.USD","LU2023250504.SGD","LU2237443465.HKD","IE00BJLML261.HKD","LU0106261372.USD","KYMR","BK4007","LU1064131342.USD","LU1868837300.USD","LU0096364046.USD","LU1917777945.USD","KNSA","BK4533","IE00B19Z3B42.SGD","LU0109391861.USD","LU2089984988.USD","LU2265009873.SGD","LU2237443978.SGD","LU0417517546.SGD","LU2362541513.USD","LU0061475181.USD","LU1093756325.SGD","SG9999017495.SGD","LU0320765059.SGD","LU0820561909.HKD","LU2063271972.USD"],"gpt_icon":1},{"id":"2519846458","title":"Apogee Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2519846458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519846458?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:30","pubTimestamp":1741861852,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW10L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2519881071","title":"Apogee Therapeutics initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2519881071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519881071?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:16","pubTimestamp":1741860965,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector uncer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2518206282","title":"Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206282","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206282?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 02:15","pubTimestamp":1741630513,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on March 4. Tyler Van Buren has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-apogee-therapeutics-driven-by-promising-clinical-data-and-strategic-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strong-buy-recommendation-for-apogee-therapeutics-driven-by-promising-clinical-data-and-strategic-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2517994209","title":"Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2517994209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517994209?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 18:19","pubTimestamp":1741169952,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tim Anderson has maintained their bullish stance on APGE stock, giving a Buy rating on March 3. Tim Anderson has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-buy-rating-backed-by-promising-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-buy-rating-backed-by-promising-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516678336","title":"Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678336?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:56","pubTimestamp":1741089414,"startTime":"0","endTime":"0","summary":"Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Apogee Therapeutics (APGE – Research Report), with a price target of $89.00. Ed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trial-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trial-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516616230","title":"Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2516616230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516616230?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 12:02","pubTimestamp":1741060955,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q4 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE","LU2065732104.USD","PRGS","BK4097"],"gpt_icon":0},{"id":"2516498659","title":"Apogee Therapeutics Shares Rise After Positive Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516498659","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516498659?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 01:31","pubTimestamp":1741023060,"startTime":"0","endTime":"0","summary":"Shares of Apogee Therapeutics advanced after sharing positive interim results that push forward more trials of inflammatory and immunology treatments.The stock rose 6% to $33.37 on Monday. Shares have lost about a quarter of their value in 2025.The biotechnology company reported positive interim results for the Phase 1 of APG990, a product that, when combined with another product called APG777, could treat several inflammatory and immunology diseases including asthma and atopic dermatitis.Data from its Phase 1 trial for APG777 showed consistent safety results and supports the ongoing Phase 2 clinical trial, Apogee said.Based on the data, Apogee plans to start its first combination trial of APG777 and APG990 used together, in 2025.Apogee said it has enough existing cash, cash equivalents and securities to fund operations into the first quarter of 2028.It had a loss of $182.1 million in 2024, compared with a loss of $84 million the prior year. The company said it has been spending more o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516752656","title":"Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752656","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752656?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 01:16","pubTimestamp":1741022203,"startTime":"0","endTime":"0","summary":"On Monday, Apogee Therapeutics, Inc.  released interim Phase 1 results from its first-in-human trial of APG990.APG990 interim Phase 1 pharmacokinetic  data showed a half-life of approximately 60 days across doses tested.Key data from the 40-healthy subject trial showed:. APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 mL co-formulated injection of APG279  administered every three and six months.APG990 was well tolerated across all five cohorts, with doses up to 1,200mg. The most common  treatment-emergent adverse events  were headache.53% of participants observed at least one TEAE.In addition, preclinical studies of the combination of APG777 and APG990 showed potential for enhanced pharmacologic responses relative to individual agents and exhibited no safety findings at any dose level, including the hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-investigational-atopic-dermatitis-171643556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","NVIW.SI","LU2023250504.SGD","LU2089984988.USD","LU2362541513.USD","TQQQ","LU2237438978.USD","BK4139","LU0114720955.EUR","SNY","BK4007","BK4588","APGE","QLD","LU0320765992.SGD","REGN","PK","QID","BK4585","LU2362540622.SGD","LU0823416689.USD","LU0109394709.USD","SQQQ","LU2362541273.HKD","USAW.SI","USJW.SI","PSQ","BK4181","TSYW.SI","BK4218","LU0289739699.SGD","IE00BFXG1179.USD","LU0882574055.USD","LU1917777945.USD","NQmain","LU2468319806.SGD",".IXIC","LU1974910355.USD","LU0889565916.HKD","MNQmain","LU0053666078.USD","LU2106854487.HKD"],"gpt_icon":1},{"id":"2516350746","title":"Apogee Therapeutics price target raised to $116 from $110 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2516350746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516350746?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:31","pubTimestamp":1741008663,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $116 from $110 and keeps a Buy rating on the sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-raised-to-116-from-110-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-price-target-raised-to-116-from-110-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2516094680","title":"Apogee Therapeutics Reports Positive Phase 1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516094680","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516094680?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:29","pubTimestamp":1741004968,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics ( ($APGE) ) has issued an update. On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its fir...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516682668","title":"Apogee Therapeutics Full-Year Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2516682668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516682668?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:34","pubTimestamp":1741001675,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics  reported a 2024 net loss Monday of $182.1 million, widening from a loss of $84 million a year earlier.Analysts polled by FactSet expected a loss of $177.9 million.At the end of the year, cash, cash equivalents and marketable securities were $731.1 million. The company said it expects its existing cash, cash equivalents and marketable securities to allow it to fund its operating expenses into Q1 2028.Apogee shares were up 1.5% in recent premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516823136","title":"Apogee Therapeutics says cash sufficient to fund expenses into 1Q28","url":"https://stock-news.laohu8.com/highlight/detail?id=2516823136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516823136?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:25","pubTimestamp":1741001137,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities were $731.1M as of December 31, 2024, compared to $395.5M as of December 31, 2023. Based on curren...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-says-cash-sufficient-to-fund-expenses-into-1q28?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-says-cash-sufficient-to-fund-expenses-into-1q28?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516684698","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684698?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:15","pubTimestamp":1741000528,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2516684660","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684660?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:15","pubTimestamp":1741000513,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","APGE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1059},{"period":"1month","weight":-0.1473},{"period":"3month","weight":-0.1066},{"period":"6month","weight":-0.3815},{"period":"1year","weight":-0.3571},{"period":"ytd","weight":-0.2691}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.","exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction